Supervisor Elham AbolFateh
Editor in Chief Mohamed Wadie

US to Vaccinate Children -5 against Coronavirus

Thu 09 Jun 2022 | 10:30 PM
Rana Atef

The White House announced on Thursday the plan of vaccination plan for children under the age of five, by ordering ten million COVID-19 vaccine doses.

The Biden-administration set the plan ahead the approval of the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) for vaccinating those children.

Authorities also added that the doses will be provided with all needed supplies such as injection devices and small needles.

US authorities also pledged to secure all required doses to protect children from the emergence of the virus as they are targeting injecting at 85% of the children under 5.

"The Administration will continue to work with trusted messengers, including pediatricians, to make a concerted effort to ensure that all families have answers to their questions and know about the importance of getting their children vaccinated,” the statement expressed.

Previously, US drugmaker Moderna announced that it had submitted a request for an emergency use approval for its COVID-19 vaccine for children ages ranging between 6 months and 6 years.

Moderna’s Chief Executive, Stephane Bancel, said in a statement: “We believe [this vaccine] will be able to safely protect these children against SARS-CoV-2, which is so important in our continued fight against COVID -19 and will be especially welcomed by parents and caregivers.”

On the other hand, leading drug-makers Pfizer and BioNTech submitted a request to get the approval of the Food and Drug Authority (FDA) for booster shots for children between 5 and 11.

The request from the drug-makers came after a new study showed that the booster shots could give children strong immune response against COVID-19.

The booster dose will be given to children six months after receiving the essential doses.

It is worthy to mention that the US health authorities approved a second COVID-19 booster dose for two vaccines: Pfizer and Moderna, for people aged 50 and older last March.

The essential motive for issuing such a decision was raising the immune response of aged people against the Omicron variant risks.